Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 10/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.33 |
| ▸ | RXRG | P48443 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15609210 | 1.00 | LMNA (0.47) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL4140167 | 0.98 | LMNA (0.48) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL4140161 | 0.98 | LMNA (0.48) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL5480114 | 0.98 | LMNA (0.48) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL5480110 | 0.98 | LMNA (0.48) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL15609452 | 0.98 | LMNA (0.48) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL11765380 | 0.94 | LMNA (0.47) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL11765371 | 0.94 | LMNA (0.47) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL15609424 | 0.89 | ALDH1A1 (0.46) | LMNACYP3A4ALDH1A1TDP1BLM | |
| SCHEMBL15609425 | 0.89 | ALDH1A1 (0.46) | LMNACYP3A4ALDH1A1TDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087246-A1 | BIOTECHNOLOGICAL PRODUCTION OF PHYTOL | BASF SE (DE) | 2026-04-30 | — | — | WO | claimed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | claimed |
| EP-4370919-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | Imperial College Innovations Limited (GB) | 2024-05-22 | — | — | EP | claimed |
| WO-2023285832-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-01-19 | — | — | WO | claimed |
| EP-1583433-B1 | PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDS, MONOTERPENES AND TRYPTOPHAN AND/OR PHYTOL DERIVATIVES | HUNZA DI PISTOLESI ELVIRA E C (IT) | 2009-03-11 | — | — | EP | claimed |
| US-20080076721-A1 | Use of branched chain fatty acid amino acid salts and compositions thereof | ABRAHAM SAL | 2008-03-27 | — | — | US | claimed |
| EP-1583433-A1 | PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDS, MONOTERPENES AND OPTIONALLY TRYPTOPHAN AND/OR PHYTOL DERIVATIVES | Hunza di Pistolesi Elvira E C. S.a.S. (IT) | 2005-10-12 | — | — | EP | claimed |
| WO-2004062389-A1 | PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDS, MONOTERPENES AND OPTIONALLY TRYPTOPHAN AND/OR PHYTOL DERIVATIVES | HUNZA DI PISTOLESI ELVIRA & C. S.A.S. (IT) | 2004-07-29 | — | — | WO | claimed |
| US-20040138181-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | ROCHE VITAMINS INC. | 2004-07-15 | — | — | US | claimed |
| CN-1365667-A | Use of phytanic acid for treating diabetes | ROCHE VITAMINE AG (CH) | 2002-08-28 | — | — | CN | claimed |
| US-20020082298-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | F. HOFFMANN-LA ROCHE AG | 2002-06-27 | — | — | US | claimed |
| EP-1177789-A2 | Use of phytanic acid for the treatment of diabetes | Roche Vitamins AG (CH) | 2002-02-06 | — | — | EP | claimed |
| WO-1997009039-A2 | COMPOSITION COMPRISING VITAMIN F | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-13 | — | — | WO | claimed |
| WO-2026087246-A1 | BIOTECHNOLOGICAL PRODUCTION OF PHYTOL | BASF SE (DE) | 2026-04-30 | — | — | WO | disclosed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | disclosed |
| EP-4370919-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | Imperial College Innovations Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-1109920-A1 | FUSION PROTEINS, DNA MOLECULES, VECTORS, AND HOST CELLS USEFUL FOR MEASURING PROTEASE ACTIVITY | Vertex Pharmaceuticals Incorporated (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6117639-A | Screening for enzyme inhibitors against proteases, determining inhibitory activity; novel transcriptional assay using DNA molecules encoding the fusion protein substrates; Hepatitis C Virus NS3 protease or HIV aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-09-12 | — | — | US | disclosed |
| WO-2000012727-A1 | FUSION PROTEINS, DNA MOLECULES, VECTORS, AND HOST CELLS USEFUL FOR MEASURING PROTEASE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-1997009039-A2 | COMPOSITION COMPRISING VITAMIN F | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-13 | — | — | WO | disclosed |